How do tumor cells respond to HDAC inhibition?

FEBS Journal

Volumn 283, Issue 22, 2016, Pages 4032-4046

  Newbold, Andrea ^a,b   Falkenberg, Katrina J ^c   Prince, H Miles ^a,b   Johnstone, Ricky W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

apoptosis; cell cycle arrest; differentiation; histone deacetylase inhibitor; senescence; tumor immunogenicity

Indexed keywords

BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KU ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RAD51 PROTEIN; REACTIVE OXYGEN METABOLITE; HISTONE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER STEM CELL; CELL AGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; TUMOR CELL; TUMOR IMMUNOGENICITY; ACETYLATION; CELL CYCLE; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ACETYLATION; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL DIFFERENTIATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS;

EID: 84966604775     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13746     Document Type: Review

References (150)

1. Berdasco M & Esteller M (2013) Genetic syndromes caused by mutations in epigenetic genes. Hum Genet 132, 359–383.
2. Surani MA, Hayashi K & Hajkova P (2007) Genetic and epigenetic regulators of pluripotency. Cell 128, 747–762.
3. Dawson MA & Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27.
4. Falkenberg KJ & Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discovery 13, 673–691.
5. Mummaneni P & Shord SS (2014) Epigenetics and oncology. Pharmacotherapy 34, 495–505.
6. Bose P, Dai Y & Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143, 323–336.
7. Chun P (2015) Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 38, 933–949.
8. Li Z & Zhu WG (2014) Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci 10, 757–770.
9. West AC & Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124, 30–39.
10. Leder A & Leder P (1975) Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 5, 319–322.
11. Riggs MG, Whittaker RG, Neumann JR & Ingram VM (1977) n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268, 462–464.
12. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA & Marks PA (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93, 5705–5708.
13. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA & Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95, 3003–3007.
14. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV & Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840.
15. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S & Pelicci PG (2004) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11, 71–76.
16. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F et al. (2004) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11, 77–84.
17. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL et al. (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104, 8071–8076.
18. Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE & Johnstone RW (2008) Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 7, 1066–1079.
19. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW et al. (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114, 380–393.
20. Matthews GM, Newbold A & Johnstone RW (2012) Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 116, 165–197.
21. Bolden JE, Shi W, Jankowski K, Kan C-Y, Cluse L, Martin BP, MacKenzie KL, Smyth GK & Johnstone RW (2013) HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 4, e519.
22. Pérez-Perarnau A, Coll-Mulet L, Rubio-Patiño C, Iglesias-Serret D, Cosialls AM, González-Gironès DM, de Frias M, de Sevilla AF, de la Banda E, Pons G et al. (2011) Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 6, 1228–1235.
23. Inoue S, Riley J, Gant TW, Dyer MJ & Cohen GM (2007) Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21, 1773–1782.
24. Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM & Yang CR (2016) Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget 7, 402–417.
25. Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A & Dent P (2013) Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther 14, 982–996.
26. Kang Y, Nian H, Rajendran P, Kim E, Dashwood WM, Pinto JT, Boardman LA, Thibodeau SN, Limburg PJ, Löhr CV et al. (2014) HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis 5, e1476.
27. Zhang Y, Adachi M, Kawamura R & Imai K (2006) Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 13, 129–140.
28. Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks K-M, Ralli R, Scott CL, Frenzel A, Villunger A et al. (2011) Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 71, 3603–3615.
29. Xargay-Torrent S, López-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roué G & Colomer D (2011) Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res 17, 3956–3968.
30. Ramsey MR, He L, Forster N, Ory B & Ellisen LW (2011) Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res 71, 4373–4379.
31. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET & Yu Q (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102, 16090–16095.
32. Yang Y, Zhao Y, Liao W, Yang J, Wu L, Zheng Z, Yu Y, Zhou W, Li L, Feng J et al. (2009) Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia 11, 313–324.
33. Brochier C, Dennis G, Rivieccio MA, McLaughlin K, Coppola G, Ratan RR & Langley B (2013) Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J Neurosci 33, 8621–8632.
34. Waby JS, Chirakkal H, Yu C-W, Griffiths GJ, Benson RSP, Bingle CD & Corfe BM (2010) Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9, 1–16.
35. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG & Keating MJ (2012) Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119, 1162–1172.
36. Zhao Z-N, Bai J-X, Zhou Q, Yan B, Qin W-W, Jia L-T, Meng Y-L, Jin B-Q, Yao L-B, Wang T et al. (2012) TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One 7, e45133.
37. Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB & Michael MZ (2013) Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 52, 459–474.
38. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y et al. (2010) Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 9, 246–256.
39. McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB & Waugh DJJ (2012) Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res 18, 3822–3833.
40. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR et al. (2010) The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 5, e10941.
41. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ & Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98, 10833–10838.
42. Rosato RR, Almenara JA, Dai Y & Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2, 1273–1284.
43. Yu C, Rahmani M, Conrad D, Subler M, Dent P & Grant S (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102, 3765–3774.
44. Dai Y, Rahmani M, Dent P & Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25, 5429–5444.
45. Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW & Grant S (2011) Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 10, 1686–1697.
46. Ungerstedt JS, Sowa Y, Xu W-S, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X & Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102, 673–678.
47. Butler LM, Zhou X, Xu W-S, Scher HI, Rifkind RA, Marks PA & Richon VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99, 11700–11705.
48. Xu W, Ngo L, Perez G, Dokmanovic M & Marks PA (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103, 15540–15545.
49. Robert C & Rassool FV (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116, 87–119.
50. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM & Buggy JJ (2007) HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 104, 19482–19487.
51. Lee J-H, Choy ML, Ngo L, Foster SS & Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107, 14639–14644.
52. Wiegmans AP, Yap P-Y, Ward A, Lim YC & Khanna KK (2015) Differences in expression of key DNA damage repair genes after epigenetic-induced BRCAness dictate synthetic lethality with PARP1 inhibition. Mol Cancer Ther 14, 2321–2331.
53. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst KSQ, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L et al. (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 5, e11208.
54. Chen Y, Jungsuwadee P, Vore M, Butterfield DA & St. Clair DK (2007) Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interventions 7, 147–156.
55. Petruccelli LA, Dupéré-Richer DD, Pettersson F, Retrouvey H, Skoulikas S & Miller WH Jr (2011) Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 6, e20987.
56. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI & Pommier Y (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70, 4470–4480.
57. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun Z-W & Hiebert SW (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30, 61–72.
58. Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper A et al. (2013) Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One 8, e68915.
59. Groselj B, Sharma NL, Hamdy FC, Kerr M & Kiltie AE (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108, 748–754.
60. Zhu L, Wu K, Ma S & Zhang S (2015) HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer. Tumori 101, 257–262.
61. Reed SM & Quelle DE (2015) p53 acetylation: regulation and consequences. Cancers 7, 30–69.
62. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA & Johnstone RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63, 4460–4471.
63. Seo S-K, Jin H-O, Woo S-H, Kim Y-S, An S, Lee J-H, Hong S-I, Lee K-H, Choe T-B & Park I-C (2011) Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 6, 1313–1319.
64. Condorelli F, Gnemmi I, Vallario A, Genazzani AA & Canonico PL (2008) Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153, 657–668.
65. Bolden JE, Peart MJ & Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discovery 5, 769–784.
66. Lindemann RK, Gabrielli B & Johnstone RW (2004) Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3, 777–786.
67. Zhang Z, Hao C, Wang L, Liu P, Zhao L, Zhu C & Tian X (2013) Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors. Onco Targets Ther 6, 733–740.
68. Jin J-S, Tsao T-Y, Sun P-C, Yu C-P & Tzao C (2012) SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol Oncol Res 18, 713–720.
69. Gabrielli B, Brooks K & Pavey S (2012) Defective cell cycle checkpoints as targets for anti-cancer therapies. Front Pharmacol 3, 1–6.
70. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG & Gabrielli BG (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11, 2069–2083.
71. Mateo F, Vidal-Laliena M, Canela N, Busino L, Martinez-Balbas MA, Pagano M, Agell N & Bachs O (2009) Degradation of cyclin A is regulated by acetylation. Oncogene 28, 2654–2666.
72. Newbold A, Salmon JM, Martin BP, Stanley K & Johnstone RW (2014) The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma. Oncogene 33, 5415–5423.
73. Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, Fornace AJ, Pospelova TV & Pospelov VA (2010) p21Waf1 is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle 9, 3945–3955.
74. Xu WS, Perez G, Ngo L, Gui CY & Marks PA (2005) Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65, 7832–7839.
75. Cho J-H, Dimri M & Dimri GP (2015) MicroRNA-31 Is a Transcriptional Target of Histone Deacetylase Inhibitors and A Regulator of Cellular Senescence. J Biol Chem 290, 10555–10567.
76. Li Z, Wang Y, Yuan C, Zhu Y, Qiu J, Zhang W, Qi B, Wu H, Jinhai YJ, Jiang H et al. (2014) Oral and gastrointestinal systems; oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer. Lab Invest 94, 1431–1445.
77. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P & Bhalla K (2006) Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 5, 3096–3104.
78. Ablain J & de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117, 5795–5802.
79. Minucci S, Nervi C, Lo Coco F & Pelicci PG (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110–3115.
80. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20, 6969–6978.
81. Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S & de Thé H (2012) Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26, 1630–1637.
82. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH & Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811–814.
83. Fredly H, Gjertsen BT & Bruserud O (2013) Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 5, 1–13.
84. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F et al. (2006) Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66, 8903–8911.
85. Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J et al. (2014) Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 123, 1341–1352.
86. Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W et al. (2007) Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 321, 953–960.
87. Yang G, Thompson MA, Brandt SJ & Hiebert SW (2007) Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 26, 91–101.
88. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA et al. (2011) Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 71, 2686–2696.
89. Hrzenjak A, Moinfar F, Kremser M-L, Strohmeier B, Staber PB, Zatloukal K & Denk H (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5, 2203–2210.
90. Yamashita Y-I, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S & Sugimachi K (2003) Histone deacetylase inhibitor trichostatin a induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103, 572–576.
91. Platta CS, Greenblatt DY, Kunnimalaiyaan M & Chen H (2007) The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142, 219–226.
92. Munster PN, Troso-Sandoval T, Rosen N, Rifkind RA, Marks PA & Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61, 8492–8497.
93. Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F et al. (2013) The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res 19, 6520–6531.
94. Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL et al. (2014) Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther 8, 1979–1990.
95. Dickinson M, Johnstone RW & Prince HM (2010) Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 28, 3–20.
96. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang K-D, Snyder DS, Huettner CS, Shultz L, Holyoake T et al. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427–442.
97. Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H et al. (2012) Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle 11, 3219–3226.
98. Lee SH, Nam HJ, Kang HJ, Samuels TL, Johnston N & Lim YC (2015) Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. Oncol Rep 34, 2065–2071.
99. Chiao MT, Cheng WY, Yang YC, Shen CC & Ko JL (2013) Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy 9, 1509–1526.
100. Di Pompo G, Salerno M, Rotili D, Valente S, Zwergel C, Avnet S, Lattanzi G, Baldini N & Mai A (2015) Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J Med Chem 58, 4073–4079.
101. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, Botrugno OA, Parazzoli D, Oldani A, Minucci S et al. (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471, 74–79.
102. Shao Y, Gao Z, Marks PA & Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101, 18030–18035.
103. Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM & Kim HS (2012) Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 9, 881–893.
104. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR & Chen CC (2010) Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 6, 1057–1065.
105. Gammoh N, Marks PA & Jiang X (2012) Curbing autophagy and histone deacetylases to kill cancer cells. Autophagy 8, 1521–1522.
106. Dupéré-Richer D, Kinal M, Ménasché V, Nielsen TH, del Rincon S, Pettersson F & Miller WH Jr (2013) Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death Dis 4, e486.
107. Zhang J, Ng S, Wang J, Zhou J, Tan S-H, Yang N, Lin Q, Xia D & Shen H-M (2015) Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways. Autophagy 11, 629–642.
108. Newbold A, Vervoort SJ, Martin BP, Bots M & Johnstone RW (2012) Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors. Cell Death Dis 3, e387.
109. El-Khoury V, Pierson S, Szwarcbart E, Brons NHC, Roland O, Cherrier-De Wilde S, Plawny L, Van Dyck E & Berchem G (2014) Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia 28, 1636–1646.
110. Oehme I, Linke J-P, Böck BC, Milde T, Lodrini M, Hartenstein B, Wiegand I, Eckert C, Roth W, Kool M et al. (2013) Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci USA 110, E2592–E2601.
111. Stankov MV, El Khatib M, Thakur BK, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K et al. (2014) Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 28, 577–588.
112. Murakami T, Sato A, Chun NAL, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki M, Furukawa Y & Kobayashi E (2008) Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 128, 1506–1516.
113. Magner WJ & Tomasi TB (2000) Chromatin-immune connections: regulation of MHC and other genes. J Reprod Immunol 48, 1–15.
114. Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J & Reinis M (2008) Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123, 218–227.
115. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB & Jefferies WA (2008) Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68, 9601–9607.
116. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja PG, Seto E, Weber J et al. (2013) The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res 23, 341–348.
117. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A et al. (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65, 6321–6329.
118. Skov S, Pedersen MT, Andresen L, Thor Straten P, Woetmann A & Ødum N (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65, 11136–11145.
119. Wu X, Tao Y, Hou J, Meng X & Shi J (2012) Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia 12, 1178–1189.
120. López-Soto A, Folgueras AR, Seto E & Gonzalez S (2009) HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 28, 2370–2382.
121. Lee S-H, Lee S-J, Kim TM & Heo DS (2008) The study of NKG2D ligand expression and NK cell cytotoxicity after HDAC inhibitors in lung cancer cell lines. Cancer Res 68, 4646.
122. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13, 54–61.
123. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira J-P, Delaloge S et al. (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220, 47–59.
124. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1bold beta-dependent adaptive immunity against tumors. Nat Med 15, 1170–1178.
125. Christiansen AJ, West A, Banks K-M, Haynes NM, Teng MW, Smyth MJ & Johnstone RW (2011) Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci USA 108, 4141–4146.
126. West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ & Johnstone RW (2013) An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 73, 7265–7276.
127. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M & Cerwenka A (2013) Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 122, 684–693.
128. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15, 9–14.
129. Nimmanapalli R, Fuino L, Stobaugh C, Richon V & Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101, 3236–3239.
130. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang H-G, Atadja P & Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2, 971–984.
131. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280, 26729–26734.
132. Krämer OH, Mahboobi S & Sellmer A (2014) Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol Sci 35, 501–509.
133. Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJP, Banks K-M, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA et al. (2013) Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther 12, 2709–2721.
134. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M & Grant S (2011) HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 17, 3219–3232.
135. Johnstone RW & Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13–18.
136. Wang Y, Wang SY, Zhang XH, Zhao M, Hou CM, Xu YJ, Du ZY & Yu XD (2007) FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 18, 998–1003.
137. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE & Thiele CJ (2002) MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62, 6108–6115.
138. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ & Johnstone RW (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102, 3697–3702.
139. Stumpel DJPM, Schneider P, Seslija L, Osaki H, Williams O, Pieters R & Stam RW (2012) Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 26, 682–692.
140. Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, Jove R, Forman SJ, Yen Y & Kirschbaum MH (2011) Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 71, 3912–3920.
141. Hideshima T, Cottini F, Ohguch H, Jakubikova J, Gorgun G, Mimura N, Tai Y-T, Munshi NC, Richardson PG & Anderson KC (2015) Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J 5, e312.
142. Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet P, Vey N, Nadel B, Collette Y et al. (2014) Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia (T-ALL). Oncotarget 5, 3168–3172.
143. Shin D-Y, Kim A, Kang HJ, Park S, Kim DW & Lee S-S (2015) Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma. Cancer Lett 364, 89–97.
144. Garcia-Sanz P, Quintanilla A, Lafita MC, Moreno-Bueno G, García-Gutierrez L, Tabor V, Varela I, Shiio Y, Larsson L-G, Portillo F et al. (2014) Sin3b interacts with Myc and decreases Myc levels. J Biol Chem 289, 22221–22236.
145. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N et al. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29, 5957–5968.
146. Zhang X, Zhao X, Fiskus W, Lin L, Lwin T, Rao R, Zhang Y, Chan JC, Fu F, Marquez VE et al. (2012) Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 22, 506–523.
147. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E et al. (2012) Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31, 3002–3008.
148. Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L et al. (2016) miR-34a silences c-SRC to attenuate tumor growth in triple negative breast cancer. Cancer Res 76, 927–939.
149. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi JS, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917.
150. Ito T, Umehara T, Sasaki K, Nakamura Y, Nishino N, Terada T, Shirouzu M, Padmanabhan B, Yokoyama S, Ito A et al. (2011) Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol 18, 495–507.